External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

External broker reports(aggregated public sources)

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>GSS is commercialising EasyScreen molecular (PCR-based) diagnostic tests, based on its patented 3base technology.</li><li>The technology allows the EasyScreen tests to detect more disease causing microorganisms with fewer PCR primers and probe sets, delivering improved sensitivity and accuracy.</li><li>GSS is preparing to file for FDA clearance of its Enteric Protozoan kit, which offers unrivalled capacity to detect these important causes of gastrointestinal disease outbreaks.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

GSS is commercialising EasyScreen molecular (PCR-based) diagnostic tests, based on its patented 3base technology.The technology allows the EasyScreen tests to detect more disease causing microorganisms with fewer PCR primers and probe sets, delivering improved sensitivity and accuracy.GSS is preparing to file for FDA clearance of its Enteric Protozoan kit, which offers unrivalled capacity to detect these important causes of gastrointestinal disease outbreaks.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Genetic Signatures (GSS) - On Track for US Launch in 2023

Australia

Genetic Signatures Ltd. develops and commercializes molecular diagnostic platform. The Company offers products for the routine detection of infectious diseases and pathogens. Genetic Signatures serves the hospitals and pathology laboratories in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Genetic Signatures (GSS AU)

Genetic Signatures (GSS) - On Track for US Launch in 2023

GSS is preparing to file for FDA clearance of its Enteric Protozoan kit, which offers unrivalled capacity to detect these important causes of...

Taylor Collison

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)